OP40
Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10)
liquid, clone RAS 10, Calbiochem®
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
NACRES:
NA.43
Prodotti consigliati
Origine biologica
mouse
Livello qualitativo
Forma dell’anticorpo
purified antibody
Tipo di anticorpo
primary antibodies
Clone
RAS 10, monoclonal
Forma fisica
liquid
contiene
≤0.1% sodium azide as preservative
Reattività contro le specie
human, mouse, rat
Produttore/marchio commerciale
Calbiochem®
Condizioni di stoccaggio
do not freeze
Isotipo
IgG2a
Condizioni di spedizione
wet ice
Temperatura di conservazione
2-8°C
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... KRAS(3845)
Descrizione generale
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 myeloma cells (see application references). Recognizes the ~21 kDa Ras protein.
Recognizes the ~21 kDa H-, K-, and N-Ras proteins in SW480 and Y1 cells and breast carcinoma tissue.
This Anti-Pan-Ras (Ab-3) Mouse mAb (RAS 10) is validated for use in FC, Frozen Sections, Immunoblotting, IF, IP, Paraffin Sections for the detection of Pan-Ras (Ab-3).
Immunogeno
recombinant human p21 Ras
Applicazioni
Flow Cytometry (2.5 g/ml)
Frozen Sections (2.5 g/ml)
Immunoblotting (0.1-3 g/ml, chemiluminescent and colorimetric, see application references)
Immunofluorescence (2.5 g/ml, see application references)
Immunoprecipitation (1 g/sample)
Paraffin Sections (2.5 g/ml, saponin pre-treatment required)
Confezionamento
Please refer to vial label for lot-specific concentration.
Attenzione
Toxicity: Standard Handling (A)
Risultati analitici
Positive Control
SW480 or Y1 cells or breast carcinoma tissue
SW480 or Y1 cells or breast carcinoma tissue
Altre note
Rodenhuis, S. et al., 1992. Cancer Res. (Suppl)52, 2665s.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
Sidransky, D., et al. 1992. Science256, 102.
Hamer, P.J., et al. 1990. Hybridoma9, 573.
Bos, J.L. 1989. Cancer Res.49, 4682.
Furth, M. E., et al. 1987. Oncogene1, 47.
Kraus, M.H., et al. 1984. Proc. Natl. Acad. Sci. USA81, 5384.
Shimizu, K., et al. 1983. Proc. Natl. Acad. Sci. USA80, 2112.
Taparowsky, E., et al. 1983. Cell34, 581.
Ellis, R.W., et al. 1981. Nature292, 506.
Shih, T.Y., et al. 1980. Nature287, 686.
The level of expression of p21ras is variable in different tissues. For this reason we recommend a concentration step prior to immunoblot analysis to obtain optimal results. Antibody should be titrated for optimal results in individual systems.
Note legali
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 1
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
J M English et al.
The Journal of biological chemistry, 274(44), 31588-31592 (1999-10-26)
The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-1 in cells, which suggests that ERK5 might mediate Raf-independent signaling by Ras. We found that Raf-1 does contribute to Ras activation
Lauren L Fonseca et al.
Translational oncology, 14(1), 100880-100880 (2020-10-20)
Ras mutations are present in only a subset of sporadic human cutaneous squamous cell carcinomas (cSCC) even though Ras is activated in most. This suggests that other mechanisms of Ras activation play a role in the disease. The aberrant expression
Qing-Fen Li et al.
Cell reports, 24(11), 2869-2882 (2018-09-13)
Cerebrovascular malformations (CVMs) affect approximately 3% of the population, risking hemorrhagic stroke, seizures, and neurological deficits. Recently Ras mutations have been identified in a majority of brain arterio-venous malformations. We generated an endothelial-specific, inducible HRASV12 mouse model, which results in
Christian H Klein et al.
International journal of cancer, 144(4), 767-776 (2018-09-09)
Ras proteins, most notably KRas, are prevalent oncogenes in human cancer. Plasma membrane localization and thereby signaling of KRas is regulated by the prenyl-binding protein PDEδ. Recently, we have reported the specific anti-proliferative effects of PDEδ inhibition in KRas-dependent human
A Pelosi et al.
Oncogene, 32(31), 3648-3654 (2012-09-12)
MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.